TPP and Access to Medicines

Share Facebook

Twitter

Email

TPP and Access to Medicines



The Trans-Pacific Partnership (TPP) was a proposed free trade agreement between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and Vietnam. Official publication of the text in November 2015 revealed that the U.S. Trade Representative (USTR) was successful in pressuring TPP countries to accept some of its proposed rules that expand pharmaceutical monopoly protections and trade away access to medicines. Resistance to USTR demands prevented some harmful rules from being included in the agreement, but many bad rules remained. By stopping the ratification of the deal in national legislatures like the U.S. Congress, people power prevented the TPP’s harmful rules from coming into effect.

Public Citizen and our partners envision a very different Asia-Pacific region partnership–one that advances pharmaceutical access and innovation simultaneously. Through analysis, and advocacy, we worked to spotlight the implications of the TPP for public health and the knowledge economy in the U.S. and other TPP countries and helped countries push back against Big Pharma’s corporate influence.

Washington Post Editorial Board: “No issue caused more conflict in the latest round of talks — or in the general political debate over the TPP — than the question of intellectual property and other protections for the U.S. pharmaceutical industry.” (August 2015)

October 9, 2015 – WikiLeaks releases the TPP intellectual property chapter — see Public Citizen’s analysis here

Fact Sheets & Analyses

​

TPP Negotiations Rounds Archive

For more info and updates, follow us on Twitter: @PCMedsAccess

Back to Access to Medicines Home Page